Client login

API, Chemical Development & Analytical Services / Robust Analytical Support for Late-Stage Biocatalytic Process Development

Poster

Back

Robust Analytical Support for Late-Stage Biocatalytic Process Development

Gain insight into how Almac Sciences delivers robust analytical support for late-stage biocatalytic process development. From method development and enzyme characterisation to troubleshooting and stability studies, this flyer highlights the expertise and capabilities that enable confident progression toward commercialisation.

View the full flyer to learn more.

View Resource

Almac API, Chemical Development, Analytical & Solid State Services

Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).

We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.

Learn More

We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.

Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.

Learn More

You may also be interested in

Article

A Concise Enantioselective Formal Synthesis of the Second-Generation Oral Contraceptive Levonorgestrel

Article

Diastereoselective Total Synthesis of the Key Synthetic Precursor of the Third-Generation Oral Contraceptive Etonogestrel

Stay up-to-date with the latest from Almac

Join our mailing list

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies

Download here instantly

A Concise Enantioselective Formal Synthesis of the Second-Generation Oral Contraceptive Levonorgestrel

Diastereoselective Total Synthesis of the Key Synthetic Precursor of the Third-Generation Oral Contraceptive Etonogestrel